Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On Business of Biotech podcast, the CEO shares Vaxxinity's strategy, what "democratization" and "revolution" really mean and a whole lot more. Listen now.
For peptide APIs, using a liquid phase peptide synthesis (LPPS) approach offers a cost-effective process for large-scale manufacture by eliminating the need for specialized equipment and excess raw materials.
Early planning for scale-up and biologics license application activities can maximize your chances of success by allowing sufficient time to develop launch options and prevent costly delays and setbacks.
Late-phase development requires a holistic development strategy driven by a well-defined target product profile. This webinar aims to provide you with an overview of the complex path to a successful product launch.